<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01536288</url>
  </required_header>
  <id_info>
    <org_study_id>NSC 99-3114-B-182A-002</org_study_id>
    <nct_id>NCT01536288</nct_id>
  </id_info>
  <brief_title>Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness</brief_title>
  <official_title>Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Traditional folk medicine in the Arctic and Himalayan areas used Rhodiola species to enhance
      physical endurance, prevent aging, resist acute mountain sickness (AMS), and to treat
      fatigue, depression, anemia, impotence and respiratory infections. Rhodiola crenulata are
      widely used to prevent AMS in Himalayan areas and Lhasa in Tibet but none was examined by
      human study. The investigators conducted a randomized, double blind, placebo controlled,
      crossover study to investigate the efficacy of Rhodiola crenulata in preventing AMS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The number of people traveling to altitude for work or for recreation is rising, and
      increased media attention towards these activities has also raised the profile of altitude
      related illness. The most effective preventive measure for acute mountain sickness
      (AMS)—gradual ascent—is frequently difficult or impractical for modern international travel
      to locations such as Lhasa in Tibet (3650 m) and La Paz in Bolivia (3740 m). In order to
      solve this problem, prophylactic acetazolamide was most commonly used. But prescription
      needed and side effects such as paresthesia and nausea are the disadvantage of using
      acetazolamide. Some over-the-counter herbal supplements with essentially no adverse effect
      were widely used, such as Rhodiola species. Rhodiola crenulata are widely used to prevent AMS
      in Himalayan areas and Lhasa in Tibet but none was examined by human study. The investigators
      conducted a randomized, double blind, placebo controlled, crossover study to investigate the
      efficacy of Rhodiola crenulata in preventing AMS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence measured by Lake Louise acute mountain sickness score (LLS) ≥ 3 with headache and one other symptom.</measure>
    <time_frame>within 18 hours after ascent to altitude 3100m</time_frame>
    <description>The LLS rates 5 symptoms (headache, gastrointestinal symptoms such as nausea and vomiting, fatigue and/or weakness, dizziness and/or light-headedness, and difficulty sleeping), with each item graded on a scale from 0 to 3. A score of 3 points or greater constitutes AMS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood oxygen content</measure>
    <time_frame>on arrival of altitude 3100m</time_frame>
    <description>Blood oxygen content was measured by pulse oximetry (NPB 40, Nellcor, Pleasanton, CA, USA) within 1-2 hours after ascent to altitude 3100m.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>severe AMS</measure>
    <time_frame>within 18 hours after ascent to altitude 3100m</time_frame>
    <description>Incidence measured by Lake Louise acute mountain sickness score (LLS) ≥ 5 with headache and one other symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>severity of headache, incidence of headache and severe headache</measure>
    <time_frame>Within 18 hours after ascent to altitude 3100m</time_frame>
    <description>severe headache is determined by cut off between scores of 1 and 2 on the Lake Louise survey (ascending scale of 0-3 for severity)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Acute Mountain Sickness</condition>
  <condition>Environmental Illness</condition>
  <arm_group>
    <arm_group_label>Rhodiola crenulata-placebo sequence</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rhodiola crenulata for the first treatment period and placebo for the second treatment period, with a washout period of 4 months. Overall study population were 120 subjects, who were randomised and allocated into 2 sequences.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Rhodiola crenulata sequence</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo for the first treatment period and Rhodiola crenulata for the second treatment period, with a washout period of 4 months. Overall study population were 120 subjects, who were randomised and allocated into 2 sequences.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rhodiola crenulata</intervention_name>
    <description>Rhodiola crenulata:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering</description>
    <arm_group_label>Rhodiola crenulata-placebo sequence</arm_group_label>
    <arm_group_label>Placebo-Rhodiola crenulata sequence</arm_group_label>
    <other_name>Rhodiola</other_name>
    <other_name>Golden root</other_name>
    <other_name>Hong Jing Tian</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering</description>
    <arm_group_label>Rhodiola crenulata-placebo sequence</arm_group_label>
    <arm_group_label>Placebo-Rhodiola crenulata sequence</arm_group_label>
    <other_name>Starch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 20 and 55 years.

          -  able to complete the study protocol of 9-day study regimens and mountain climbing
             twice.

          -  no prophylactic medication or herb one month before ascent.

          -  maintaining the same living conditions and habits four months before the first
             mountain climbing and four months between two mountaineering.

               -  living in the same altitude or within a difference of 200 meters.

               -  no additional physical training.

               -  no plan to gain or loss weight.

               -  no altitude exposure above 2500m.

        Exclusion Criteria:

          -  any history of chronic obstructive pulmonary disease, heart failure, cerebral
             neoplasm, mania, renal or hepatic insufficiency.

          -  women in pregnancy or intending of pregnancy during the 4-month study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Te-Fa Chiu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept of Emergency medicine, Chang Gung Memorial Hospital</name>
      <address>
        <city>Kweishan</city>
        <state>Taoyuan</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.liebertpub.com/products/product.aspx?pid=65</url>
    <description>High Altitude Medicine &amp; Biology</description>
  </link>
  <link>
    <url>http://www.ismmed.org/</url>
    <description>International society of mountain medicine</description>
  </link>
  <link>
    <url>http://department.tpa.edu.tw/medical/new_page_8.htm</url>
    <description>Prevention and management of AMS, Taiwan police college</description>
  </link>
  <link>
    <url>http://hospital.kingnet.com.tw/essay/essay.html?category=%C2%E5%C3%C4%AFe%AFf&amp;pid=13719</url>
    <description>Acute mountain sickness, Kingnet, national web hospital</description>
  </link>
  <link>
    <url>http://www.acep.org/</url>
    <description>American college emergency physicians</description>
  </link>
  <link>
    <url>http://www.wilderness-medicine.com/</url>
    <description>wilderness medicine, medicine and the spirit of adventure</description>
  </link>
  <reference>
    <citation>Hackett PH, Roach RC. High-altitude illness. N Engl J Med. 2001 Jul 12;345(2):107-14. Review.</citation>
    <PMID>11450659</PMID>
  </reference>
  <reference>
    <citation>Imray C, Booth A, Wright A, Bradwell A. Acute altitude illnesses. BMJ. 2011 Aug 15;343:d4943. doi: 10.1136/bmj.d4943. Review.</citation>
    <PMID>21844157</PMID>
  </reference>
  <reference>
    <citation>Chow T, Browne V, Heileson HL, Wallace D, Anholm J, Green SM. Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo-controlled trial. Arch Intern Med. 2005 Feb 14;165(3):296-301.</citation>
    <PMID>15710792</PMID>
  </reference>
  <reference>
    <citation>Hackett PH, Rennie D, Levine HD. The incidence, importance, and prophylaxis of acute mountain sickness. Lancet. 1976 Nov 27;2(7996):1149-55.</citation>
    <PMID>62991</PMID>
  </reference>
  <reference>
    <citation>Zell SC, Goodman PH. Acetazolamide and dexamethasone in the prevention of acute mountain sickness. West J Med. 1988 May;148(5):541-5.</citation>
    <PMID>3051673</PMID>
  </reference>
  <reference>
    <citation>Dumont L, Mardirosoff C, Tramèr MR. Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. BMJ. 2000 Jul 29;321(7256):267-72. Review.</citation>
    <PMID>10915127</PMID>
  </reference>
  <reference>
    <citation>Basnyat B, Gertsch JH, Holck PS, Johnson EW, Luks AM, Donham BP, Fleischman RJ, Gowder DW, Hawksworth JS, Jensen BT, Kleiman RJ, Loveridge AH, Lundeen EB, Newman SL, Noboa JA, Miegs DP, O'Beirne KA, Philpot KB, Schultz MN, Valente MC, Wiebers MR, Swenson ER. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Alt Med Biol. 2006 Spring;7(1):17-27.</citation>
    <PMID>16544963</PMID>
  </reference>
  <reference>
    <citation>Imray C, Wright A, Subudhi A, Roach R. Acute mountain sickness: pathophysiology, prevention, and treatment. Prog Cardiovasc Dis. 2010 May-Jun;52(6):467-84. doi: 10.1016/j.pcad.2010.02.003. Review.</citation>
    <PMID>20417340</PMID>
  </reference>
  <reference>
    <citation>Leadbetter G, Keyes LE, Maakestad KM, Olson S, Tissot van Patot MC, Hackett PH. Ginkgo biloba does--and does not--prevent acute mountain sickness. Wilderness Environ Med. 2009 Spring;20(1):66-71. doi: 10.1580/08-WEME-BR-247.1.</citation>
    <PMID>19364166</PMID>
  </reference>
  <reference>
    <citation>Gertsch JH, Basnyat B, Johnson EW, Onopa J, Holck PS. Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ. 2004 Apr 3;328(7443):797. Epub 2004 Mar 11.</citation>
    <PMID>15070635</PMID>
  </reference>
  <reference>
    <citation>Gertsch JH, Seto TB, Mor J, Onopa J. Ginkgo biloba for the prevention of severe acute mountain sickness (AMS) starting one day before rapid ascent. High Alt Med Biol. 2002 Spring;3(1):29-37.</citation>
    <PMID>12006162</PMID>
  </reference>
  <reference>
    <citation>van Patot MC, Keyes LE, Leadbetter G 3rd, Hackett PH. Ginkgo biloba for prevention of acute mountain sickness: does it work? High Alt Med Biol. 2009 Spring;10(1):33-43. doi: 10.1089/ham.2008.1085. Review.</citation>
    <PMID>19278351</PMID>
  </reference>
  <reference>
    <citation>Zhang ZJ, Tong Y, Zou J, Chen PJ, Yu DH. Dietary supplement with a combination of Rhodiola crenulata and Ginkgo biloba enhances the endurance performance in healthy volunteers. Chin J Integr Med. 2009 Jun;15(3):177-83. doi: 10.1007/s11655-009-0177-x. Epub 2009 Jul 2.</citation>
    <PMID>19568709</PMID>
  </reference>
  <reference>
    <citation>Tu Y, Roberts L, Shetty K, Schneider SS. Rhodiola crenulata induces death and inhibits growth of breast cancer cell lines. J Med Food. 2008 Sep;11(3):413-23. doi: 10.1089/jmf.2007.0736.</citation>
    <PMID>18800886</PMID>
  </reference>
  <reference>
    <citation>Nakamura S, Li X, Matsuda H, Yoshikawa M. Bioactive constituents from Chinese natural medicines. XXVIII. Chemical structures of acyclic alcohol glycosides from the roots of Rhodiola crenulata. Chem Pharm Bull (Tokyo). 2008 Apr;56(4):536-40.</citation>
    <PMID>18379104</PMID>
  </reference>
  <reference>
    <citation>Zheng KY, Guo AJ, Bi CW, Zhu KY, Chan GK, Fu Q, Xu SL, Zhan JY, Lau DT, Dong TT, Choi RC, Tsim KW. The extract of Rhodiolae Crenulatae Radix et Rhizoma induces the accumulation of HIF-1α via blocking the degradation pathway in cultured kidney fibroblasts. Planta Med. 2011 Jun;77(9):894-9. doi: 10.1055/s-0030-1250627. Epub 2010 Dec 14.</citation>
    <PMID>21157678</PMID>
  </reference>
  <reference>
    <citation>Zhao Y, Qi LW, Wang WM, Saxena PK, Liu CZ. Melatonin improves the survival of cryopreserved callus of Rhodiola crenulata. J Pineal Res. 2011 Jan;50(1):83-8. doi: 10.1111/j.1600-079X.2010.00817.x. Epub 2010 Nov 15.</citation>
    <PMID>21073518</PMID>
  </reference>
  <reference>
    <citation>Lee OH, Kwon YI, Apostolidis E, Shetty K, Kim YC. Rhodiola-induced inhibition of adipogenesis involves antioxidant enzyme response associated with pentose phosphate pathway. Phytother Res. 2011 Jan;25(1):106-15. doi: 10.1002/ptr.3236.</citation>
    <PMID>20623718</PMID>
  </reference>
  <reference>
    <citation>Li T, Zhang H. Identification and comparative determination of rhodionin in traditional tibetan medicinal plants of fourteen Rhodiola species by high-performance liquid chromatography-photodiode array detection and electrospray ionization-mass spectrometry. Chem Pharm Bull (Tokyo). 2008 Jun;56(6):807-14.</citation>
    <PMID>18520085</PMID>
  </reference>
  <reference>
    <citation>Li T, Zhang H. Application of microscopy in authentication of traditional Tibetan medicinal plants of five Rhodiola (Crassulaceae) alpine species by comparative anatomy and micromorphology. Microsc Res Tech. 2008 Jun;71(6):448-58. doi: 10.1002/jemt.20570.</citation>
    <PMID>18300292</PMID>
  </reference>
  <reference>
    <citation>Kwon YI, Jang HD, Shetty K. Evaluation of Rhodiola crenulata and Rhodiola rosea for management of type II diabetes and hypertension. Asia Pac J Clin Nutr. 2006;15(3):425-32.</citation>
    <PMID>16837437</PMID>
  </reference>
  <reference>
    <citation>Panossian A, Wikman G, Sarris J. Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy. Phytomedicine. 2010 Jun;17(7):481-93. doi: 10.1016/j.phymed.2010.02.002. Epub 2010 Apr 7. Review.</citation>
    <PMID>20378318</PMID>
  </reference>
  <reference>
    <citation>Wang S, Wang FP. [Studies on the chemical components of Rhodiola crenulata]. Yao Xue Xue Bao. 1992;27(2):117-20. Chinese.</citation>
    <PMID>1414365</PMID>
  </reference>
  <reference>
    <citation>Wang S, You XT, Wang FP. [HPLC determination of salidroside in the roots of Rhodiola genus plants]. Yao Xue Xue Bao. 1992;27(11):849-52. Chinese.</citation>
    <PMID>1300030</PMID>
  </reference>
  <reference>
    <citation>Wang SH, Chen YC, Kao WF, Lin YJ, Chen JC, Chiu TF, Hsu TY, Chen HC, Liu SW. Epidemiology of acute mountain sickness on Jade Mountain, Taiwan: an annual prospective observational study. High Alt Med Biol. 2010 Spring;11(1):43-9. doi: 10.1089/ham.2009.1063.</citation>
    <PMID>20367488</PMID>
  </reference>
  <reference>
    <citation>Karinen HM, Peltonen JE, Kähönen M, Tikkanen HO. Prediction of acute mountain sickness by monitoring arterial oxygen saturation during ascent. High Alt Med Biol. 2010 Winter;11(4):325-32. doi: 10.1089/ham.2009.1060.</citation>
    <PMID>21190501</PMID>
  </reference>
  <reference>
    <citation>Roach RC, Greene ER, Schoene RB, Hackett PH. Arterial oxygen saturation for prediction of acute mountain sickness. Aviat Space Environ Med. 1998 Dec;69(12):1182-5.</citation>
    <PMID>9856544</PMID>
  </reference>
  <reference>
    <citation>Jackson SJ, Varley J, Sellers C, Josephs K, Codrington L, Duke G, Njelekela MA, Drummond G, Sutherland AI, Thompson AA, Baillie JK. Incidence and predictors of acute mountain sickness among trekkers on Mount Kilimanjaro. High Alt Med Biol. 2010 Fall;11(3):217-22. doi: 10.1089/ham.2010.1003.</citation>
    <PMID>20919888</PMID>
  </reference>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2012</study_first_submitted>
  <study_first_submitted_qc>February 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2012</study_first_posted>
  <last_update_submitted>February 21, 2012</last_update_submitted>
  <last_update_submitted_qc>February 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute mountain sickness</keyword>
  <keyword>AMS</keyword>
  <keyword>Rhodiola Crenulata</keyword>
  <keyword>mountaineering</keyword>
  <keyword>pulse oximetry</keyword>
  <keyword>oxygen saturation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Altitude Sickness</mesh_term>
    <mesh_term>Environmental Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

